Bristol Myers: positive results in active PsA

(CercleFinance.com) - Bristol Myers Squibb reports positive data from the pivotal Phase 3 POETYK PsA-2 trial (IM011-055) evaluating the efficacy and safety of Sotyktu in adults with active psoriatic arthritis (PsA), presented at the AAD 2025 Annual Meeting.


The trial met its primary endpoint, with a significantly higher proportion of patients achieving an ACR20 response (at least 20% improvement in disease signs and symptoms) compared to placebo at week 16 (54.2% vs. 39.4%).

In addition, the overall safety profile of Sotyktu after 16 weeks of treatment was consistent with that established in a Phase 2 clinical trial in psoriatic arthritis and a Phase 3 trial in moderate-to-severe plaque psoriasis.


Copyright (c) 2025 CercleFinance.com. All rights reserved.